\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesHORIZON-CL4-2022-HUMAN-02
A total of 128 proposals has been submitted to the call HORIZON-CL4-2022-HUMAN-02, these proposals were submitted to the below mentioned topics:
HORIZON-CL4-2022-DIGITAL-EMERGING-02
A total of 266 proposals has been submitted to the call HORIZON-CL4-2022-DIGITAL-EMERGING-02, these proposals were submitted to the below mentioned topics:
For all above mentioned proposals, the evaluation will be organized over the coming weeks and months.
Source: Funding and Tender Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The following call topics under the Digital Europe programme are now open for submission: Apply AI: Piloting AI-based image screening in medical centres Digital solutions for regulatory compliance through data Advanced Digital Skills for AI Uptake in Health EdTech Accelerator Digital Skills and Jobs Platform: The National Coalitions for Digi... read more
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
